This document is a published patent application from the USPTO for "Compositions and Methods for Treating Cancer." The application, filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat, specifically discloses compositions and methods for modulating K-Ras, identified as the most frequently mutated oncogene in human cancer, with the aim of treating cancer.

As this is a patent application, it represents a disclosure of potential new intellectual property rather than a regulatory requirement. Companies in the pharmaceutical and biotechnology sectors involved in oncology research and development may find the disclosed compositions and methods of interest for potential licensing, collaboration, or competitive analysis. No immediate compliance actions or deadlines are imposed by a patent application itself.